A recent phase I trial of 13 patients (<65 years) with newly diagnosed Ph+ ALL investigated multicycle-sequential anti-CD19 CAR-T plus autologous CD19+ feeding T cells in combination with a TKI as consolidation therapy. Here, CD19 is linked to acute lymphoblastic leukemia.